期刊文献+

熊去氧胆酸对人肝内胆管瘢痕成纤维细胞生长影响的研究 被引量:1

The effects of ursodeoxycholic acid on scar fibroblast growth in human intrahepatic bile ducts
下载PDF
导出
摘要 目的 探讨熊去氧胆酸(UDCA)对人肝内胆管瘢痕成纤维细胞生长的影响。方法 原代培养人肝内胆管瘢痕组织成纤维细胞。通过显微镜观察和免疫荧光染色鉴定细胞,采用噻唑蓝(MTT)法和划痕实验检测UDCA对瘢痕成纤维细胞生长的影响。结果 ①成功原代培养人肝内胆管瘢痕成纤维细胞;②MTT显示:CA和DCA浓度在0.5∽10.0μmol/L之间促进细胞活力,而UDCA浓度大于5μmol/L时,则明显抑制细胞的活力(〈0.05)。随着UDCA浓度升高,CA组和DCA组细胞活力逐渐下降;③划痕实验结果显示:随着UDCA浓度升高,CA组和DCA组细胞愈合距离逐渐增加。结论 UDCA可能抑制CA和DCA的促瘢痕成纤维细胞生长的作用。 [ Objective ] To discuss the effects of UDCA on scar fibroblasts growth of human intrahepatic bile ducts. [ Methods ] The primary scar fibroblast cells in human intrahepatic bile ducts were cultured . The cells were identified by cell morphology and immunofluorescence staining. The growth of scar fibroblast was tested by MTT method and Wound-Healing. [ Results ] (1)Scar fibroblasts in human intrahepatic bile duct were successfully cultured. (2) MTT results showed in the concentration of 0.5 to 10 μmol/L, CA and DCA increased the scar fibroblast viability, 〉20μmol/L, UDCA inhibited the growth of scar fibroblasts. With increasing concentration of UDCA, the cell viability of CA group or DCA group was gradually declined. (3)With increasing concentration of UDCA, the dis- tance healing of the CA group and DCA group was gradually increased. [ Conclusions ] UDCA may inhibit CA and DCA from promoting scar fibroblasts growth.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第4期1-5,共5页 China Journal of Modern Medicine
基金 国家自然科学基金(No:81260084)
关键词 胆管瘢痕 成纤维细胞 熊去氧胆酸 胆酸 去氧胆酸 bile duct scar fibroblast ursodeoxycholic acid cholic acid deoxycholate acid
  • 相关文献

参考文献14

  • 1刘剑毅,李世荣,纪淑兴.病理性瘢痕中结缔组织生长因子基因的表达[J].中国修复重建外科杂志,2003,17(6):436-438. 被引量:28
  • 2ZHANG Q, WU Y, ANN DK, et al. Mechanisms of hypoxic reg- ulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts[J]. J Inves Dcrmato, 2003, 121(5): 1005-1012.
  • 3LEAD, ZHANG Q, WU Y, et al. Elevated vascular endothelial growth factor in keloid: relevance to tissue fibrosis[J]. Ceils Tis- sues Organs, 2004, 176(1/3): 87-94.
  • 4RIDLON JM, KANG DJ, HYLEMON PB. Bile salt biotransfor- mations by human intestinal bacteria[J]. J Lipid Res, 2006, 47 (2): 241-259.
  • 5SHI J, WU C, LIN Y, et al. Long-term effects of mid-dose ur- sodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials[J]. Am J Gastroenterol, 2006, 101(7):1529-1538.
  • 6CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemi- cal response to umodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48(3): 871-877.
  • 7MYERS RP, SWAIN MG, LEE SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J]. Am J Gastroenterol, 2013, 108(6): 933- 941.
  • 8ZHANG LX, LIANG TJ, TAN YR, et al. Protective effects of ursodeoxycholic acid against immune-mediated liver fibrosis in rats[J]. Hepatogastroenterology, 2010, 57(102-103): 1196-1202.
  • 9朱疆依,时永全,韩者艺,贾桂,李增山,黄晓峰,王建宏,王瑞安,周新民,韩英.熊去氧胆酸联合糖皮质激素治疗自身免疫性肝炎-原发性胆汁性肝硬化重叠综合征的疗效观察[J].中华肝脏病杂志,2011,19(5):334-339. 被引量:16
  • 10OLSSON R, BOBERG KM, DE MUCKADELL OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangi- tis: a 5-year muhicenter, randomized, controlled study [J]. Gas- troenterology, 2005, 129(5): 1464-1472.

二级参考文献13

共引文献56

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部